Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;77(1):50-59.
doi: 10.1016/j.rec.2023.05.003. Epub 2023 May 20.

Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry

[Article in English, Spanish]
Marta Cobo Marcos  1 , Rafael de la Espriella  2 , Jara Gayán Ordás  3 , Pau Llàcer  4 , Antonia Pomares  5 , Aleix Fort  6 , Inés Ponz de Antonio  7 , Ana Méndez  8 , Zorba Blázquez-Bermejo  9 , Pedro Caravaca Pérez  10 , Jorge Rubio Gracia  11 , Alejandro Recio-Mayoral  12 , Isabel Zegrí  5 , José Manuel García Pinilla  13 , Esther Montero Hernández  14 , Almudena Castro  7 , María José Soler  15 , José Luis Górriz  16 , Ramón Bascompte Claret  3 , Paula Fluvià-Brugués  6 , Luis Manzano  17 , Julio Núñez  18
Affiliations

Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry

[Article in English, Spanish]
Marta Cobo Marcos et al. Rev Esp Cardiol (Engl Ed). 2024 Jan.

Abstract

Introduction and objectives: Patients with combined heart failure (HF) and chronic kidney disease (CKD) have been underrepresented in clinical trials. The prevalence of CKD in these patients and their clinical profile require constant evaluation. This study aimed to analyze the prevalence of CKD, its clinical profile, and patterns of use of evidence-based medical therapies in HF across CKD stages in a contemporary cohort of ambulatory patients with HF.

Methods: From October 2021 to February 2022, the CARDIOREN registry included 1107 ambulatory HF patients from 13 HF clinics in Spain.

Results: The median age was 75 years, 63% were male, and 48% had heart failure with reduced left ventricular ejection fraction (HFrEF). A total of 654 (59.1%) had an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2, and 122 (11%) patients with eGFR ≥ 60 mL/min/1.73 m2 had a urine albumin-creatinin ratio ≥ 30 mg/g. The most important variables associated with lower eGFR were age (R2=61%) and furosemide dose (R2=21%). The proportion of patients receiving an angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin II receptor blockers (ARB), an angiotensin receptor-neprilysin inhibitor (ARNi), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), or a mineralocorticoid receptor antagonist (MRA) progressively decreased with lower eGFR categories. Notably, 32% of the patients with HFrEF and an eGFR <30 mL/min/1.73 m2 received the combination of ACEI/ARB/ARNi+beta-blockers+MRA+SGLT2i.

Conclusions: In this contemporary HF registry, 70% of patients had kidney disease. Although this population is less likely to receive evidence-based therapies, structured and specialized follow-up approaches within HF clinics may facilitate the adoption of these life-saving drugs.

Keywords: Cardiorenal disease; Cardiorenal syndrome; Enfermedad cardiorrenal; Enfermedad renal; Heart failure; Insuficiencia cardiaca; Kidney disease; Síndrome cardiorrenal.

PubMed Disclaimer

Substances